Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2004-06-24
2009-12-15
Lam, Ann Y (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C435S007100, C435S014000, C435S019000, C435S021000, C435S040500, C435S040520, C435S188000, C436S503000, C436S518000, C436S164000, C549S218000, C549S398000, C558S190000
Reexamination Certificate
active
07632652
ABSTRACT:
The invention is directed to novel compositions of matter and methods of detecting in situ an immunohistochemical epitope or nucleic acid sequence of interest in a biological sample comprising binding an enzyme-labeled conjugate molecule to the epitope or sequence of interest in the presence of a redox-inactive reductive species and a soluble metal ion, thereby facilitating the reduction of the metal ion to a metal atom at or about the point where the enzyme is anchored. Novel phosphate derivatives of reducing agents are described that when exposed to a phosphatase are activated to their reducing form, thereby reducing metal ions to insoluble metal.
REFERENCES:
patent: 5073483 (1991-12-01), Lebacq
patent: 5116734 (1992-05-01), Higgs et al.
patent: 5143854 (1992-09-01), Pirrung et al.
patent: 5252743 (1993-10-01), Barrett et al.
patent: 5355439 (1994-10-01), Bernstein et al.
patent: 5384261 (1995-01-01), Winkler et al.
patent: 5412087 (1995-05-01), McGall et al.
patent: 5424186 (1995-06-01), Fodor et al.
patent: 5445934 (1995-08-01), Fodor et al.
patent: 5451683 (1995-09-01), Barrett et al.
patent: 5510270 (1996-04-01), Fodor et al.
patent: 5571639 (1996-11-01), Hubbell et al.
patent: 5595707 (1997-01-01), Copeland et al.
patent: 5599695 (1997-02-01), Pease et al.
patent: 5624711 (1997-04-01), Sundberg et al.
patent: 5631734 (1997-05-01), Stern et al.
patent: 5654199 (1997-08-01), Copeland et al.
patent: 5677195 (1997-10-01), Winkler et al.
patent: 5681755 (1997-10-01), Noppe et al.
patent: 5737499 (1998-04-01), Bernstein et al.
patent: 5744101 (1998-04-01), Fodor et al.
patent: 5981185 (1999-11-01), Matson et al.
patent: 6083726 (2000-07-01), Mills, Jr. et al.
patent: 6093574 (2000-07-01), Druyor-Sanchez et al.
patent: 6670113 (2003-12-01), Hainfeld
patent: 2002/0142411 (2002-10-01), Hainfeld
patent: WO 90/15070 (1990-12-01), None
patent: WO 92/10092 (1992-06-01), None
patent: WO 93/09668 (1993-05-01), None
patent: WO 97/10365 (1997-03-01), None
patent: WO03/035900 (2003-05-01), None
Merchenthaler, et al, Journal of Histochem Cytochem, vol. 37 (No. 10) p. 1563-1565 (Oct. 1989).
Meur, et al, A New Technique for Localization of Cellulase In-Situ Using Silver Nitrate, Stain Technology, vol. 58 (No. 2), (1983)Abst. only.
Partanen, A Direct Coloring Metal Precipitation Method for the Demonstration of Aryl Sulfatase A and Aryl Sulfatase B, Histochemical Journal, vol. 16 (No. 5), (1984), Abstract only.
Patton, Detection Technologies in Proteme Analysis, Journal of Chromatography B., vol. 771 (No. 1-2), p. 3-31, (May 5, 2002).
Chee, M., et al, “Accessing Genetic Information with High-Density DNA Arrays,” Science, 1996, vol. 274, p. 601-614.
Danscher, G., et al, “Gold and Silver Staining: Techniques in Molecular Morphology,” Apr. 2002, p. 13-69, CRS Press, Baca Raton, FL.
Meur, S.A., et al, “A New Technique for Localization of Cellulase in Situ Using Sliver Nitrate,” Stain Technol., 1983, vol. 58, p. 97-100.
Partanen, S. “A Direct-Colouring, Metal Precipitation Method for the Demonstration of Arylsulphatases A and B,” Histochem. J. 1984, vol. 16, p. 501-506.
Sia, S.K., et al, “An Integrated Approach to a Portable and Low-Cost Immunoassay for Resource-Poor Settings,” Angew. Chem., Int., Ed. 43, Jan. 2004, p. 498-502.
Sigma Technical Bulletin No. 1, SE 1, Jan. 1989, Silver Enhancer Kit, Product No. SE-100, p. 1-6.
Azoulay, M., et al, “Prodrugs of anthracycline antibiotics suited for tumor-specific activation,” Anticancer Drug Des. Sep. 1995, vol. 10, No. 6, p. 441-450 (Abstract only).
Bagshawe, K., et al, “Antibody-directed enzyme prodrug therapy (ADEPT) for cancer,” Expert Opin. Biol. Ther., 2004, vol. 4, No. 11, p. 1777-1789.
Bakina, E., et al, “Intensely cytotoxic anthracycline prodrugs: galactosides,”, Anticancer Drug Des., Dec. 1999, vol. 14, No. 6, p. 507-515 (Abstract only).
Bieniarz, C., et al, “Chromogenic Redox Assay for Beta-Lactamases Yielding Water-Insoluble Products,” Analytical Biochem., 1992, vol. 207, p. 329-334.
Cheng, H., et al, “Synthesis and enzyme-specific activation of carbohydrate-geldanamycin conjugates with potent anticancer activity,” J. Med. Chem., Jan. 27, 2005, vol. 48, No. 2, p. 645-652 (Abstract only).
Farquhar, D., et al, “Suicide gene therapy usingE. colibeta-galactosidase,” Cancer Chemother. Pharmacol, Jul. 2002, vol. 50, No. 1, p. 65-70 (Abstract only).
Fujimoto, Z., et al, “Crystal Structure of Rice a-Galactosidase Complexed with D-Galactose,” Journal of Biological Chemistry, May 30, 2003, vol. 278, No. 22, p. 20313-20318.
Harding. F., et al, “A beta-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy,” Mol. Cancer Ther., Nov. 2005, vol. 4, No. 11, p. 1791-1800.
Han, H., “Targeted Prodrug Design to Optimize Drug Delivery,” AAPS Pharmsci 2000, Mar. 21, 2000, vol. 2, No. 1, Article 6 (http://www.pharmsci.org/), p. 1-11.
Hult, K., et al “Enzyme promiscuity: mechanism and applications,” Trends in Biotechnology, 2007, vol. 25, No. 5, p. 231-238.
Isorna, P., et al, “Crystal Structures of Paenibacillus polymyxa beta-Glucosidase B Complexes Reveal the Molecular Basis of Substrate Specificity and Give New Insights into the Catalytic Machinery of Family 1 Glycosidases,” J. Mol. Biol, Aug. 31, 2007, vol. 371, No. 5, p. 1204-1218 (Abstract only).
Niculescu-Duvaz, I., et al, “Antibody-directed enzyme prodrug therapy (ADEPT): a review,” Advanced Drug Delivery Reviews, 1997, vol. 26, p. 151-172.
Rooseboom, M., et al, “Enzyme-Catalyzed Activation of Anticancer Prodrugs,” Pharmacol. Rev., 2004, vol. 56, p. 53-102.
Sanz-Aparicio, J., et al, “Crystal structure of beta-glucosidase A from Bacillus polymyxa: insights into the catalytic activity in family 1 glycosyl hydrolases,” J. Mol. Biol. Jan. 23, 1998, vol. 275, No. 3, p. 491-502 (Abstract only).
Senter, P., et al, “Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates,” Advanced Drug Delivery Reviews, 2001, vol. 53, p. 247-264.
Smyth, TP, et al, “Extending the beta-Lactamase-Dependent Prodrug Armory: S-Aminosulfeniminocephalosporins as Dual-Release Prodrugs,” J. Org.Chem., Apr. 30, 1999, vol. 64, No. 9, p. 3132-3138 (Abstract only).
Xu, G., et al, “Strategies for Enzyme/Prodrug Cancer Therapy,” Clinical Research Center, Nov. 2001, vol. 7, p. 3314-3324.
Beiniarz, C. et al, “Chromogenic Redox Assay for Beta-Lactamases Yielding Water-Insoluble Products,” Analytical Biochemistry, 1992, vol. 207, p. 321-328.
Bieniarz Christopher
Kernag Casey A.
Kosmeder Jerome W.
Rodgers Paula
Wong Jennifer
Grun James L
Lam Ann Y
Ventana Medical Systems, Inc.
LandOfFree
Enzyme-catalyzed metal deposition for the enhanced in situ... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enzyme-catalyzed metal deposition for the enhanced in situ..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enzyme-catalyzed metal deposition for the enhanced in situ... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4096049